BOSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results